Detalhe da pesquisa
1.
Cytomegalovirus antiviral resistance among participants in the phase 3 trial of letermovir vs valganciclovir prophylaxis in kidney transplant recipients.
J Infect Dis
; 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38853607
2.
Letermovir safety and efficacy for cytomegalovirus prophylaxis in adult Japanese kidney transplant recipients: a multicenter, open-label, noncomparative Phase 3 study.
Clin Exp Nephrol
; 2024 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38615067
3.
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance.
Ann Hepatol
; 28(2): 100899, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36632975
4.
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Ann Intern Med
; 175(9): 1221-1229, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35939812
5.
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
JAMA
; 330(1): 33-42, 2023 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279999
6.
Craniofacial reconstructions in children with craniosynostosis.
J Integr Neurosci
; 21(4): 106, 2022 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35864758
7.
Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.
J Viral Hepat
; 27(11): 1222-1233, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32594612
8.
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.
Liver Int
; 40(5): 1042-1051, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31765046
9.
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis.
J Viral Hepat
; 26(3): 329-336, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30412325
10.
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Hepatology
; 67(6): 2113-2126, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29473975
11.
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
J Gastroenterol Hepatol
; 34(9): 1597-1603, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30779220
12.
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Gastroenterology
; 152(6): 1372-1382.e2, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28193518
13.
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Gastroenterology
; 152(1): 164-175.e4, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27720838
14.
Neurodevelopmental Outcome of Young Children with Biliary Atresia and Native Liver: Results from the ChiLDReN Study.
J Pediatr
; 196: 139-147.e3, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29519540
15.
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
Hepatology
; 66(3): 736-745, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28256747
16.
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Hepatology
; 65(2): 439-450, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27770561
17.
Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant-Reply.
JAMA
; 330(18): 1803-1804, 2023 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37962654
18.
Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.
Hepatol Res
; 47(12): 1340-1345, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28334495
19.
Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection.
J Pediatr Gastroenterol Nutr
; 64(1): 89-94, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27111344
20.
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1087-97, 2015 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25467560